RT Journal Article
SR Electronic
T1 Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255308
DO 10.1101/2021.04.12.21255308
A1 de Faria, Elizabeth
A1 Guedes, Ana Rubia
A1 Oliveira, Maura S.
A1 de Godoy Moreira, Moacyr Vergara
A1 Maia, Fernando Liebhart
A1 dos Santos Barboza, Antonio
A1 Leme, Mariana Deckers
A1 Letaif, Leila S. Harima
A1 Miethke-Morais, Anna
A1 Bonfá, Eloisa
A1 Segurado, Aluisio C.
A1 Tomazini, Francis M.
A1 dos Santos, Alcir Alves
A1 Figueiredo, Pedro
A1 dos Santos Andrade, Pâmela
A1 de Oliveira, Franciane Mendes
A1 de Araújo Eliodoro, Raissa Heloisa
A1 de Jesus, Jaqueline Goes
A1 dos Santos Lazari, Carolina
A1 Sabino, Ester C.
A1 Costa, Silvia F.
A1 Pedroso de Lima, Antonio Carlos
A1 Levin, Anna S.
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255308.abstract
AB Background CoronaVac, a vaccine containing inactivated SARS-CoV-2, demonstrated efficacy of 50.39% 14 days or more after the 2nd dose.The objective of this study is to report the occurrence of symptomatic COVID-19 in a cohort of HCW vaccinated with CoronaVac and to estimate its effectiveness.Methods CoronaVac was given to HCWs inHospital das Clinicas on 18-21 January, 2021 (epi week 3) (22,402 HCWs), and on 14-16 February, 2021 (epi week 7) (21,652 HCWs). Weekly cases of symptomatic COVID-19 were evaluated. Using the period from 2020 epi week 24 through 2021 epi week 2 (before vaccination), a Poisson regression was fit to model the HCWs with COVID-19 of the hospital, and the officially reported cases in the city of São Paulo. The predicted numbers of cases among HCWs for 2021 epi weeks 3-12 were then compared to the observed numbers of cases (after vaccination). Effectiveness was estimated for weeks 9-12 (2 to 5 weeks after the 2nd dose). 142 samples after vaccination were evaluated for SARS-CoV-2 variants of concern.Results Since the 1st dose there were 380 HCW diagnosed with COVID-19. On visual analysis, the number of cases of COVID-19 in the city increased sharply in 2021. The number of cases among the HCW did not follow. The estimated effectiveness 2 and 3 weeks after 2nd dose was 50.7% and 51.8%, respectively, and increased over the next 2 weeks. 67/142 samples (47%) were variants of concern, mostly P1 (57).Conclusion Coronavac is effective in preventing COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by Hospital das Clinicas.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study is part of a more ample project approved by the IRB of Hospital das Clinicas.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.